{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:31:55Z","timestamp":1782754315478,"version":"3.54.5"},"reference-count":171,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Even though an approved vaccine for hepatitis B virus (HBV) is available and widely used, over 257 million individuals worldwide are living with chronic hepatitis B (CHB) who require monitoring of treatment response, viral activity, and disease progression to reduce their risk of HBV-related liver disease. There is currently a lack of predictive markers to guide clinical management and to allow treatment cessation with reduced risk of viral reactivation. Novel HBV biomarkers are in development in an effort to improve the management of people living with CHB, to predict disease outcomes of CHB, and further understand the natural history of HBV. This review focuses on novel HBV biomarkers and their use in the clinical setting, including the description of and methodology for quantification of serum HBV RNA, hepatitis B core-related antigen (HBcrAg), quantitative hepatitis B surface antigen (qHBsAg), including ultrasensitive HBsAg detection, quantitative anti-hepatitis B core antigen (qAHBc), and detection of HBV nucleic acid-related antigen (HBV-NRAg). The utility of these biomarkers in treatment-na\u00efve and treated CHB patients in several clinical situations is further discussed. Novel HBV biomarkers have been observed to provide critical clinical information and show promise for improving patient management and our understanding of the natural history of HBV.<\/jats:p>","DOI":"10.3390\/v13060951","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T02:32:43Z","timestamp":1621823563000},"page":"951","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management"],"prefix":"10.3390","volume":"13","author":[{"given":"Alicia","family":"Vachon","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada"},{"name":"National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-7220","authenticated-orcid":false,"given":"Carla","family":"Osiowy","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada"},{"name":"National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"ref_1","unstructured":"WHO (2021, April 02). Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/hep4.1460","article-title":"Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics","volume":"4","author":"Joshi","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","article-title":"Overview of hepatitis B viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.virusres.2007.12.024","article-title":"Hepatitis B viruses: Reverse transcription a different way","volume":"134","author":"Nassal","year":"2008","journal-title":"Virus Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bpg.2017.05.003","article-title":"Hepatitis B virus infection and the immune response: The big questions","volume":"31","author":"Boeijen","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(01)00172-4","article-title":"Immunology of hepatitis B infection","volume":"2","author":"Jung","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: Towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Song, J.E., and Kim, D.Y. (2016). Diagnosis of hepatitis B. Ann. Transl. Med., 4.","DOI":"10.21037\/atm.2016.09.11"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s11033-020-06056-4","article-title":"Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach","volume":"48","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.22065","article-title":"HBeAg and hepatitis B Virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B","volume":"47","author":"Fried","year":"2008","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1440-1746.2010.06282.x","article-title":"Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients","volume":"25","author":"Ma","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.3748\/wjg.v12.i41.6693","article-title":"Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive","volume":"12","author":"Shin","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_15","first-page":"1","article-title":"Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0222196","article-title":"Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening","volume":"14","author":"Kuo","year":"2019","journal-title":"PLoS ONE"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.7150\/ijms.51799","article-title":"INR-to-platelet ratio (INPR) as a novel noninvasive index for predicting liver fibrosis in chronic hepatitis B","volume":"18","author":"Ding","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/135965350601100704","article-title":"One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels","volume":"11","author":"Wong","year":"2006","journal-title":"Antivir. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/jvh.12261","article-title":"Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss","volume":"21","author":"Zheng","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3851\/IMP3225","article-title":"Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B","volume":"23","author":"Hagiwara","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.30082","article-title":"Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection","volume":"68","author":"Butler","year":"2018","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2021.656353","article-title":"Antiviral Activity of Interferon Alpha-Inducible Protein 27 Against Hepatitis B Virus Gene Expression and Replication","volume":"12","author":"Ullah","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jvh.13150","article-title":"Effects of pegylated interferon-\u03b1 based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"26","author":"Ren","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11901-020-00534-w","article-title":"Targeting Viral cccDNA for Cure of Chronic Hepatitis B","volume":"19","author":"Ligat","year":"2020","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: From discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_28","first-page":"689","article-title":"Percutaneous Liver Biopsy","volume":"2","year":"2006","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JCM.01275-19","article-title":"Diagnostic value of detection of pregenomic RNA in sera of hepatitis B virus-infected patients with different clinical outcomes","volume":"58","author":"Lin","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/jvh.13260","article-title":"Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection","volume":"27","author":"Ou","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Charre, C., Levrero, M., Zoulim, F., and Scholt\u00e8s, C. (2019). Non-invasive biomarkers for chronic hepatitis B virus infection management. Antiviral Res., 169.","DOI":"10.1016\/j.antiviral.2019.104553"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","author":"Bartens","year":"2015","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Stadelmayer, B., Diederichs, A., Chapus, F., Rivoire, M., Alam, A., Fraisse, L., Carter, K., Testoni, B., and Zoulim, F. (2020). Full-length 5\u2019RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum. J. Hepatol.","DOI":"10.1016\/j.jhep.2020.01.028"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jhep.2017.08.021","article-title":"Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients","volume":"68","author":"Wang","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1128\/jvi.65.8.4284-4291.1991","article-title":"Diversity of hepatitis B virus X gene-related transcripts in hepatocellular carcinoma: A novel polyadenylation site on viral DNA","volume":"65","author":"Hilger","year":"1991","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.antiviral.2016.04.007","article-title":"Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors","volume":"131","author":"Zhang","year":"2016","journal-title":"Antiviral Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2013.06.018","article-title":"Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma","volume":"59","author":"Bayliss","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mak, L.-Y.L., Cloherty, G., Wong, D.K.-H.K., Gersch, J., Seto, W.W.-K., Fung, J., and Yuen, M.-F.M. (2020). HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy. Hepatology.","DOI":"10.1002\/hep.31616"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/hep.29872","article-title":"Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment","volume":"68","author":"Pfefferkorn","year":"2018","journal-title":"Hepatology"},{"key":"ref_41","first-page":"1","article-title":"Serum HBV RNA quantification: Useful for monitoring natural history of chronic hepatitis B infection","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/jvh.12908","article-title":"Natural history of serum HBV-RNA in chronic HBV infection","volume":"25","author":"Wang","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wang, M.L., Liao, J., Ye, F., Tao, Y.C., Wu, D.B., He, M., Tang, H., and Chen, E.Q. (2020). Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients. J. Med. Virol., 1\u20139.","DOI":"10.1136\/gutjnl-2019-IDDFAbstracts.308"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JCM.00760-17","article-title":"Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?","volume":"55","author":"Gao","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jvh.13227","article-title":"Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues","volume":"27","author":"Luo","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/jvh.13272","article-title":"Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B","volume":"27","author":"Pfefferkorn","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ma, G., Lou, B., Lv, F., Zhao, D., Zhang, Z., and Chen, Y. (2020). HBcrAg and pgRNA and the therapeutic effect in HBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNA is a powerful predictor of response. J. Viral Hepat.","DOI":"10.1111\/jvh.13299"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3851\/IMP2777","article-title":"On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy","volume":"20","author":"Huang","year":"2015","journal-title":"Antivir. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00535-012-0737-2","article-title":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients","volume":"48","author":"Tsuge","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Carey, I., Gersch, J., Wang, B., Moigboi, C., Kuhns, M., Cloherty, G., Dusheiko, G., and Agarwal, K. (2020). Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology.","DOI":"10.1002\/hep.31026"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lai, C.-L., Wong, D.K.-H., Wong, G.T.-Y., Seto, W.-K., Fung, J., and Yuen, M.-F. (2020). Rebound of HBV DNA after cessation of nucleos\/tide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA. JHEP Rep., 2.","DOI":"10.1016\/j.jhepr.2020.100112"},{"key":"ref_52","first-page":"405","article-title":"Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus","volume":"23","author":"Theilmann","year":"1996","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/jmv.25792","article-title":"Reverse transcriptase droplet digital PCR vs reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification","volume":"92","author":"Limothai","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.01695-20","article-title":"Characterization of Hepatitis B Precore\/Core-Related Antigens","volume":"95","author":"Hong","year":"2021","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jmv.21339","article-title":"Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients","volume":"81","author":"Suzuki","year":"2009","journal-title":"J. Med. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/apt.16214","article-title":"Editorial: HBV cure - the quest for biomarkers to predict off-treatment sustained response","volume":"53","author":"Thibault","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Inoue, T., Kusumoto, S., Iio, E., Ogawa, S., Suzuki, T., Yagi, S., Kaneko, A., Matsuura, K., Aoyagi, K., and Tanaka, Y. (2021). Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J. Hepatol.","DOI":"10.1016\/j.jhep.2021.02.017"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Hong, X., Luckenbaugh, L., Perlman, D., Revill, P.A., Wieland, S.F., Menne, S., and Hu, J. (2021). Characterization and Application of Precore\/Core-Related Antigens in Animal Models of Hepatitis B Virus Infection. Hepatology.","DOI":"10.1002\/hep.31720"},{"key":"ref_59","unstructured":"Wu, J.-W., Kao, J.-H., and Tseng, T.-C. (2021). Three Heads are Better than Two: HBcrAg as a New Predictor of HBV-related HCC. Clin. Mol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/infdis\/jiv572","article-title":"Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma","volume":"213","author":"Honda","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_61","first-page":"1","article-title":"Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Caviglia, G.P., Armandi, A., Rosso, C., Ribaldone, D.G., Pellicano, R., and Fagoonee, S. (2021). Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. Diagnostics, 11.","DOI":"10.3390\/diagnostics11020187"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cca.2018.07.027","article-title":"Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients","volume":"486","author":"Chen","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_64","first-page":"995","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"2017","author":"Wong","year":"2016","journal-title":"Liver Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.00366-07","article-title":"Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection","volume":"45","author":"Wong","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.16258","article-title":"Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis","volume":"1","author":"Brunetto","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jvh.13061","article-title":"Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA","volume":"26","author":"Chen","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B","volume":"20","author":"Seto","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"606.e1","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cmi.2017.03.003","article-title":"Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype","volume":"23","author":"Bes","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jvh.12889","article-title":"HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues","volume":"25","author":"Wang","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.clinre.2018.10.020","article-title":"Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy","volume":"43","author":"Wang","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Tseng, T.C., Liu, C.H.C.J., Yang, W.T., Hsu, C.Y., Hong, C.M., Su, T.H., Tsai, C.H., Chen, C.L., Yang, H.C., and Liu, C.H.C.J. (2021). Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Aliment. Pharmacol. Ther., 1\u201311.","DOI":"10.1111\/apt.16266"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.13277","article-title":"Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma","volume":"49","author":"Suzuki","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cheung, K.-S., Seto, W.-K., Wong, D.K.-H., Lai, C.-L., and Yuen, M.-F. (2017). Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J. Viral Hepat., 654\u2013661.","DOI":"10.1111\/jvh.12688"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"E240","DOI":"10.1111\/hepr.12976","article-title":"Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment","volume":"48","author":"Ando","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/apt.15108","article-title":"Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues","volume":"49","author":"Hosaka","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2012.10.025","article-title":"Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis","volume":"58","author":"Kumada","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/jvh.13191","article-title":"Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma","volume":"26","author":"To","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00535-020-01700-z","article-title":"Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients","volume":"55","author":"Liang","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.canlet.2019.10.033","article-title":"Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium","volume":"469","author":"Guo","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2016.03.013","article-title":"HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics","volume":"65","author":"Tada","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cca.2019.10.049","article-title":"HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: \u201cLoss of HBsAg\u201d maybe not a good end-point of anti-viral therapy","volume":"501","author":"Ma","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"571.e5","DOI":"10.1016\/j.cmi.2016.02.002","article-title":"Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen\u2013positive chronic hepatitis B patients","volume":"22","author":"Brouwer","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"306.e7","DOI":"10.1016\/j.cmi.2017.07.016","article-title":"Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon\u2013based therapy","volume":"24","author":"Chuaypen","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Kuo, Y.H., Wang, J.H., Hung, C.H., Lu, S.N., Hu, T.H., and Chen, C.H. (2021). Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatol. Int.","DOI":"10.1007\/s12072-021-10159-w"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Lam, Y.F., Seto, W.K., Wong, D., Cheung, K.S., Fung, J., Mak, L.Y., Yuen, J., Chong, C.K., Lai, C.L., and Yuen, M.F. (2017). Seven-year treatment outcome of entecavir in a real-world cohort: Effects on clinical parameters, HBsAg and HBcrag levels. Clin. Transl. Gastroenterol., 8.","DOI":"10.1038\/ctg.2017.51"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/apt.16172","article-title":"Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss","volume":"53","author":"Brakenhoff","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_90","first-page":"1","article-title":"Correlation between hepatitis B virus DNA levels and diagnostic tests for HBsAg, HBeAg, and PreS1-Ag in chronic hepatitis B","volume":"15","author":"Liu","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/1348-0421.12852","article-title":"TIMM29 interacts with hepatitis B virus preS1 to modulate the HBV life cycle","volume":"64","author":"Muriungi","year":"2020","journal-title":"Microbiol. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2893.2000.00248.x","article-title":"Evaluation of an enzyme-linked immunosorbent assay for detection and quantification of hepatitis B virus PreS1 envelope antigen in serum samples: Comparison with two commercial assays for monitoring hepatitis B virus DNA","volume":"7","author":"Eberle","year":"2000","journal-title":"J. Viral Hepat."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2017-313811","article-title":"Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers","volume":"67","author":"Pfefferkorn","year":"2018","journal-title":"Gut"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2020.08.039","article-title":"Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B","volume":"74","author":"Pfefferkorn","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/liv.14298","article-title":"Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a","volume":"40","author":"Rinker","year":"2020","journal-title":"Liver Int."},{"key":"ref_96","first-page":"4632","article-title":"The detection of serum HBV-NRAg and HBV DNA correlation analysis","volume":"34","author":"Huang","year":"2007","journal-title":"Mod. Prev. Med."},{"key":"ref_97","unstructured":"(2021, April 02). Beijing Wantai Biological Pharmacy Enterprise WANTAI HBV NRAg ELISA; Beijing, 2007. Available online: https:\/\/www.ystwt.cn\/hepatitis-b\/."},{"key":"ref_98","first-page":"930","article-title":"Detecting Nucleic Acid Related Antigen of Hepatitis B Virus: A Clinical Study","volume":"19","author":"Zhang","year":"2008","journal-title":"Chin. J. Nosocomiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","article-title":"Durability of Spontaneous and Treatment-related Loss of Hepatitis B s Antigen","volume":"18","author":"Alawad","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.23464","article-title":"Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus","volume":"51","author":"Simonetti","year":"2010","journal-title":"Hepatology"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Park, Y., Lee, J.H., Sinn, D.H., Park, J.Y., Kim, M.A., Kim, Y.J., Yoon, J.H., Kim, D.Y., Ahn, S.H., and Kang, W. (2021). Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. Clin. Transl. Gastroenterol., 12.","DOI":"10.14309\/ctg.0000000000000290"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Pollicino, T., and Caminiti, G. (2021). HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses, 13.","DOI":"10.3390\/v13030368"},{"key":"ref_103","first-page":"2689","article-title":"Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg","volume":"42","author":"Wang","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.3748\/wjg.v24.i31.3488","article-title":"Hepatitis B virus infection: Defective surface antigen expression and pathogenesis","volume":"24","author":"Wu","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jcv.2016.06.003","article-title":"International collaborative study on the 3rd WHO International Standard for hepatitis B surface antigen","volume":"82","author":"Wilkinson","year":"2016","journal-title":"J. Clin. Virol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jcv.2014.05.013","article-title":"Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: Correlation with the ARCHITECT quantitative assays","volume":"60","author":"Burdino","year":"2014","journal-title":"J. Clin. Virol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1007\/s10620-008-0263-5","article-title":"Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment","volume":"53","author":"Ozaras","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/jmv.25080","article-title":"Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients","volume":"90","author":"Yang","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1053\/j.gastro.2007.06.057","article-title":"Impaired Intrahepatic Hepatitis B Virus Productivity Contributes to Low Viremia in Most HBeAg-Negative Patients","volume":"133","author":"Volz","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000006554","article-title":"Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients","volume":"96","author":"Ungtrakul","year":"2017","journal-title":"Medicine"},{"key":"ref_111","first-page":"142","article-title":"Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection","volume":"25","author":"Barut","year":"2014","journal-title":"Turkish J. Gastroenterol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Bowden","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","article-title":"Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response","volume":"5","author":"Chan","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jcv.2006.06.011","article-title":"Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B","volume":"37","author":"Rodella","year":"2006","journal-title":"J. Clin. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/liv.12735","article-title":"HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients","volume":"35","author":"Asselah","year":"2015","journal-title":"Liver Int."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2036.2011.04973.x","article-title":"Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"35","author":"Peng","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/MEG.0b013e3283557e23","article-title":"Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon \u03b1-2a: Progressive decrease in hepatitis B surface antigen in responders","volume":"24","author":"Rijckborst","year":"2012","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_119","first-page":"27","article-title":"Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: A Romanian cohort study","volume":"22","author":"Curescu","year":"2013","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_120","first-page":"1","article-title":"Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)","volume":"53","author":"Lim","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients \u2013 FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2018.05.047","article-title":"Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy","volume":"17","author":"Chi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term Nucleos(t)ide analogue therapy in HBeAg-negative chronic Hepatitis B","volume":"214","author":"Rinker","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Yilmaz, N., and \u00c7am, H. (2020). Quantitative HBsAg titers in relation to disease progression and serum markers of iron metabolism among chronic hepatitis B patients. Int. J. Hepatobiliary Pancreat. Dis., 10.","DOI":"10.5348\/100088Z04NY2020RA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5114\/ceh.2020.93058","article-title":"Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients","volume":"6","author":"Tatar","year":"2020","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_128","first-page":"1","article-title":"Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"11954","DOI":"10.3748\/wjg.v21.i42.11954","article-title":"Rapid and quantitative detection of hepatitis B virus","volume":"21","author":"Liu","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcv.2018.05.009","article-title":"An ultra-sensitive Abbott ARCHITECT \u00ae assay for the detection of hepatitis B virus surface antigen (HBsAg)","volume":"105","author":"Lou","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Sickinger, E., Braun, H.B., Meyer, T., Schmid, K., Daghfal, D., Oer, M., and Schultess, J. (2020). Performance characteristics of the high sensitivity Alinity i & ARCHITECT HBsAg Next Qualitative\/Confirmatory assays. Diagn. Microbiol. Infect. Dis., 97.","DOI":"10.1016\/j.diagmicrobio.2020.115033"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcla.22334","article-title":"Evaluation of the highly sensitive chemiluminescent enzyme immunoassay \u201cLumipulse HBsAg-HQ\u201d for hepatitis B virus screening","volume":"32","author":"Deguchi","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1128\/JCM.00324-13","article-title":"Highly sensitive detection of hepatitis B virus surface antigen by use of a semiautomated immune complex transfer chemiluminescence enzyme immunoassay","volume":"51","author":"Takeda","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcv.2019.08.001","article-title":"Improved detection of early acute, late acute, and occult Hepatitis B infections by an increased sensitivity HBsAg assay","volume":"118","author":"Kuhns","year":"2019","journal-title":"J. Clin. Virol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jviromet.2015.11.016","article-title":"The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen","volume":"228","author":"Yang","year":"2016","journal-title":"J. Virol. Methods"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00535-016-1244-7","article-title":"Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody","volume":"52","author":"Matsumoto","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jhep.2020.03.009","article-title":"Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma","volume":"73","author":"Kusumoto","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Fung, J., Wong, D.K.-H., Tanaka, Y., Lo, R., Wong, T., Chok, K.S.-H., Chan, A.C.-Y., Cheung, T.-T., Dai, W.-C., and Ng, K. (2018). Quantitative hepatitis B surface antigen in predicting recurrence of hepatitis B-related hepatocellular carcinoma after liver transplantation. Hepatoma Res., 4.","DOI":"10.20517\/2394-5079.2018.92"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/hepr.13229","article-title":"Clinical evaluation of a novel and highly sensitive immunoassay for anti-hepatitis B core antigen using a fully automated immunochemical analyzer","volume":"48","author":"Izumida","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_140","unstructured":"(2021, April 02). Medicines & Healthcare products Regulatory Agency WHO International Standard: First International Standard for anti-Hepatitis B core antigen. NIBSC: Herts, UK, 2013. Available online: https:\/\/www.nibsc.org\/documents\/ifu\/95-522.pdf."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jhep.2020.01.024","article-title":"Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV","volume":"73","author":"Vanwolleghem","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_142","first-page":"1","article-title":"Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-na\u00efve chronic hepatitis B patients","volume":"95","author":"Li","year":"2016","journal-title":"Medicine"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cmi.2014.10.002","article-title":"Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection","volume":"21","author":"Song","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"11063","DOI":"10.18632\/oncotarget.14323","article-title":"Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-na\u00efve patients with chronic hepatitis B","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_145","first-page":"1","article-title":"Total hepatitis B core antigen antibody, a quantitative non-invasive marker of hepatitis B virus induced liver disease","volume":"10","author":"Yuan","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jcma.2018.05.007","article-title":"Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-na\u00efve CHB patients","volume":"81","author":"Li","year":"2018","journal-title":"J. Chinese Med. Assoc."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3851\/IMP3280","article-title":"Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside\/nucleotide analogue therapy","volume":"24","author":"Liao","year":"2019","journal-title":"Antivir. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2018.02.033","article-title":"Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection","volume":"69","author":"Yang","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Zhang, Z.Q., Shi, B.S., Lu, W., Liu, D.P., Huang, D., and Feng, Y.L. (2019). Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection. Can. J. Infect. Dis. Med. Microbiol., 2019.","DOI":"10.1155\/2019\/6545642"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/hep.1840190207","article-title":"Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection","volume":"19","author":"Marinos","year":"1994","journal-title":"Hepatology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2008.01.023","article-title":"Occult hepatitis B virus in liver tissue of individuals without hepatic disease","volume":"48","author":"Raimondo","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.dld.2014.07.172","article-title":"Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers","volume":"46","author":"Tandoi","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Caviglia, G.P., Olivero, A., Ciancio, A., Tandoi, F., Troshina, G., Rosso, C., Abate, M.L., Younes, R., Ribaldone, D.G., and Smedile, A. (2020). Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. Diagn. Microbiol. Infect. Dis., 96.","DOI":"10.1016\/j.diagmicrobio.2020.114985"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cgh.2018.04.064","article-title":"Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients","volume":"17","author":"Hu","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jhep.2018.03.021","article-title":"Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection","volume":"69","author":"Caviglia","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/gutjnl-2012-302656","article-title":"Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients","volume":"62","author":"Yuan","year":"2013","journal-title":"Gut"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gutjnl-2014-308546","article-title":"Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues","volume":"65","author":"Fan","year":"2016","journal-title":"Gut"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jfma.2017.11.012","article-title":"Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B","volume":"117","author":"Tseng","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_159","unstructured":"Wu, Y., Wang, X., Lin, X., Shen, C., and Chen, X. (2019). Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance. J. Microbiol. Immunol. Infect."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3350\/cmh.2016.0069","article-title":"New perspectives of biomarkers for the management of chronic hepatitis B","volume":"22","author":"Lin","year":"2016","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Loureiro, D., Tout, I., Narguet, S., Benazzouz, S.M., Mansouri, A., and Asselah, T. (2020). miRNAs as Potential Biomarkers for Viral Hepatitis B and C. Viruses, 12.","DOI":"10.3390\/v12121440"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2020.104992","article-title":"Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B","volume":"185","author":"Tout","year":"2021","journal-title":"Antiviral Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3748\/wjg.v26.i11.1113","article-title":"Circulating microRNAs as non-invasive biomarkers for hepatitis B virus liver fibrosis","volume":"26","author":"Iacob","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.02580-20","article-title":"Distinct cytokine profiles correlate with disease severity and outcome in longitudinal studies of acute hepatitis B virus and hepatitis D virus infection in chimpanzees","volume":"11","author":"Engle","year":"2020","journal-title":"MBio"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4103\/0366-6999.237394","article-title":"Association of cytokines with alanine aminotransferase, Hepatitis B virus surface antigen and Hepatitis B envelope antigen levels in chronic Hepatitis B","volume":"131","author":"Li","year":"2018","journal-title":"Chin. Med. J."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Lei, Z., Mo, Z., Zhu, J., Pang, X., Zheng, X., Wu, Z., Wang, K., Li, X., Xie, D., and Gao, Z. (2015). Soluble ST2 plasma concentrations predict mortality in HBV-related acute-on-chronic liver failure. Mediators Inflamm., 2015.","DOI":"10.1155\/2015\/535938"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molimm.2020.01.011","article-title":"NLRP3 inflammasome and related cytokines reflect the immune status of patients with HBV-ACLF","volume":"120","author":"Jia","year":"2020","journal-title":"Mol. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Lee, H.W., Lee, J.S., and Ahn, S.H. (2021). Hepatitis B virus cure: Targets and future therapies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010213"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","article-title":"Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection","volume":"18","author":"Lee","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/6\/951\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:05:30Z","timestamp":1760162730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/6\/951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":171,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["v13060951"],"URL":"https:\/\/doi.org\/10.3390\/v13060951","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]}}}